@Valueformoney Its a one off item (and one that still irks me -...

@Valueformoney Its a one off item (and one that still irks me - they should have been made to buy on market like everyone else) but lets not forget as well the $3.5 million cash inflow from the strategic placement that also adds to the balance sheet.

....and I forgot the R&D rebate has already been confirmed and received - $3.05 million, not unlike the $3.1 million from 2023 and modelled above....

If the receipts continue to grow per above, OCC well on its way to all important positive cash flow in 2025 (IMO) with a big lump of cash still intact from the original BH deal. That sat at $20.1 million cash at the last reported Appendix 4C, but that was before the $3.05 million R&D tax rebate.

Gross profit margins on the sales receipts are only going to increase with more Remplir in the mix, but were already an impressive 43% on the half yearly accounts. Perhaps four more negative quarters yet, but with diminishing burn, that on pure recent growth and accounting trajectories should reverse 2H 25CY, providing no cost blow outs. On sales growth continuing per above, I suspect OCC will go cash flow positive with at least $12 million cash reserve still intact (maybe even $14 million) - need to DYOR on their accounting on that one, as I've given insight to above.